To compare the efficacy and safety of <font color="red">nifedipine_5</font> <font color="red">sustained_3</font> <font color="red">release_3</font> <font color="red">with_1</font> <font color="red">Ginkgo_4</font> <font color="red">biloba_4</font> <font color="red">extract_4</font> to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) . 
<br>
<br> This study examined the efficacy and safety of <font color="red">nifedipine_6</font> <font color="red">sustained_5</font> <font color="red">release_5</font> <font color="red">(_4</font> <font color="red">nifedipine_4</font> <font color="red">SR_4</font> <font color="red">)_4</font> compared with <font color="red">Ginkgo_5</font> <font color="red">biloba_5</font> <font color="red">extract_5</font> as treatment for primary Raynaud 's phenomenon ( RP ) in Korea . Primary RP were screened and assigned to either the <font color="red">nifedipine_4</font> <font color="red">SR_4</font> <font color="red">group_4</font> <font color="red">(_3</font> <font color="red">Group_3</font> <font color="red">N_3</font> <font color="red">)_3</font> <font color="red">or_1</font> <font color="red">the_1</font> <font color="red">Ginkgo_5</font> <font color="red">biloba_5</font> <font color="red">extract_5</font> <font color="red">group_4</font> <font color="red">(_2</font> <font color="red">Group_2</font> <font color="red">G_2</font> <font color="red">)_2</font> in the ratio of 2:1 . After a run - in period of 2 weeks , patients received treatment for 8 weeks . We observed the percent improvement of the RP attack rate between before and after the 8-week treatment . Ninety - three subjects were randomly assigned . The percent improvement in <font color="red">Group_1</font> <font color="red">N_1</font> was 50.1% at 8 weeks after treatment , while it was 31.0% in <font color="red">Group_1</font> <font color="red">G_1</font> ( p = 0.03 ) . No serious adverse events occurred , and almost adverse events were mild and improved without specific treatment . <font color="red">nifedipine_3</font> <font color="red">SR_3</font> was more effective than <font color="red">Ginkgo_3</font> <font color="red">biloba_3</font> <font color="red">extract_3</font> for treatment of primary RP in Korean patients . Both drugs were tolerable with primary RP patients .